MindBio Therapeutics (CVE:MBIO)

PRESS RELEASE

published on 03/20/2024 at 09:50, 2 years 6 months ago

MindBio Begins Landmark Phase 2B Take-Home Microdosing (MB22001) Clinical Trial in Patients with Major Depressive Disorder
Phase 2B trial begins with MB22001 for Major Depressive Disorder patients. Successful Phase 2A trial showed 53% in remission with 14.1 MADRS score drop. MindBio aims to scale up psychedelic treatment for depression

MB22001 Major Depressive Disorder Phase 2b MindBio Psychedelic Treatment
PRESS RELEASE

published on 03/20/2024 at 09:50, 2 years 6 months ago

MindBio Begins Landmark Phase 2B Take-Home Microdosing (MB22001) Clinical Trial in Patients with Major Depressive Disorder
MindBio Therapeutics Corp. commences Phase 2B clinical trial for MB22001 in Major Depressive Disorder patients, following successful Phase 2A trial with significant results

Psychedelic Medicine MindBio Therapeutics Corp. MB22001 Major Depressive Disorder Clinical Trial
BRIEF

published on 03/04/2024 at 11:05, 2 years 7 months ago

MindBio Therapeutics passe à l'essai de phase 2B pour la médecine psychédélique dans le trouble dépressif majeur

MindBio Thérapeutique Trouble Dépressif Majeur Essai Clinique De Phase 2B Médecine Psychédélique Microdosage Du LSD
BRIEF

published on 03/04/2024 at 11:05, 2 years 7 months ago

MindBio Therapeutics Advances to Phase 2B Trial for Psychedelic Medicine in Major Depressive Disorder

Psychedelic Medicine Major Depressive Disorder Microdosing LSD Phase 2b Clinical Trial MindBio Therapeutics
PRESS RELEASE

published on 03/04/2024 at 11:00, 2 years 7 months ago

MindBio Therapeutics Receives Final Regulatory Approval to Conduct Phase 2B Randomised Controlled Trial Microdosing Mb22001 in Patients Diagnosed with Major Depressive Disorder
Ethics and regulatory approvals finalized for world-first take-home use of psychedelic medicine MB22001 in Phase 2B randomized controlled trial for Major Depressive Disorder by MindBio Therapeutics Corp

Psychedelic Medicine MB22001 Major Depressive Disorder MindBio Therapeutics Phase 2B Trial
BRIEF

published on 02/26/2024 at 10:30, 2 years 7 months ago

MindBio annonce des résultats positifs dans un essai clinique de microdosage à domicile pour la dépression

Depression MB22001 Essai Clinique MindBio Microdosage
BRIEF

published on 02/26/2024 at 10:30, 2 years 7 months ago

MindBio Announces Positive Results in At-Home Microdosing Clinical Trial for Depression

Depression MB22001 MindBio Microdosing Clinical Test
PRESS RELEASE

published on 02/26/2024 at 10:30, 2 years 7 months ago

MindBio Therapeutics Announces Positive Depression Data from World-First Phase 2a Take-Home Microdosing Trial
MindBio announces positive top line data from its world-first take-home microdosing depression clinical trial using MB22001. Patients experienced a 60% reduction in depressive symptoms with an impressive mean 14.1 point drop in MADRS score over 8 weeks

Psychedelic Medicine Depression MB22001 Clinical Trial MindBio
PRESS RELEASE

published on 02/14/2024 at 10:00, 2 years 7 months ago

MindBio Therapeutics Completes World First Take Home Phase 2a Microdosing Depression Trial
MindBio Therapeutics Corp. completes landmark Phase 2a clinical trial in Major Depressive Disorder patients with regulatory approvals for take-home use of proprietary microdose LSD MB22001. Phase 2B trial in late-stage cancer patients ongoing. CEO Justin Hanka announces pivotal moment for psychiatric medicine development

MindBio Therapeutics Corp. Major Depressive Disorder Clinical Trial Phase 2a LSD Microdosing
PRESS RELEASE

published on 01/30/2024 at 08:10, 2 years 8 months ago

MindBio Therapeutics Nears Completion of Landmark Phase 2a LSD Microdosing (MB22001) Clinical Trial in Depressed Patients
MindBio Therapeutics Corp. is nearing completion of its Phase 2a clinical trial using MB22001 in patients with Major Depressive Disorder. The company expects top line results to be announced in March 2024. MindBio is conducting trials with regulatory approvals for take-home use of a special form of LSD in microdoses, aiming to treat mental health conditions

MindBio Therapeutics Corp. Phase 2a Clinical Trial MB22001 Major Depressive Disorder Microdosing LSD

Published on 10/09/2026 at 14:00, 5 hours 50 minutes ago

Stillwater Critical Minerals Upgrades to OTCQX Best Market, Expanding U.S. Market Presence
Published on 10/09/2026 at 14:00, 5 hours 50 minutes ago

Vogenx Appoints Board Member Richard Gorman as Chief Commercial Officer
Published on 10/09/2026 at 13:23, 6 hours 27 minutes ago

SLAM Exploration Announces Leadership Transition and Appointment of Jimmy Gravel as President and CEO
Published on 10/09/2026 at 13:00, 6 hours 50 minutes ago

Horizon Aircraft Reports Fiscal 2027 First Quarter Results and Advances Full-Scale Cavorite X7 Development
Published on 10/09/2026 at 13:00, 6 hours 50 minutes ago

Nepra Foods Launches Flagship PROPASTA Brand on Amazon

View all ACCESSWIRE

Published on 10/09/2026 at 19:22, 28 minutes ago

EQS-Adhoc: elumeo SE switches financial reporting to comply with the German Commercial Code (HGB) and refines forecast for 2026
Published on 10/09/2026 at 19:14, 36 minutes ago

Holding(s) in Company
Published on 10/09/2026 at 18:00, 1 hour 50 minutes ago

ARVERNE GROUP: Arverne franchit une étape majeure : l'Europe fait du projet Lithium de France un pilier de sa souveraineté industrielle
Published on 10/09/2026 at 18:00, 1 hour 50 minutes ago

ARVERNE GROUP: Arverne reaches a major milestone: Europe recognizes the Lithium de France Project as a pillar of its industrial sovereignty
Published on 10/09/2026 at 18:00, 1 hour 50 minutes ago

Private Equity Holding AG: Net Asset Value as of September 30, 2026

View all EQS

Published on 10/09/2026 at 19:27, 22 minutes ago

Disclosure of transactions in own shares from October 1 to October 9, 2026
Published on 10/09/2026 at 19:27, 22 minutes ago

Déclaration hebdomadaire d'opérations effectuées du 1er au 9 octobre 2026
Published on 10/09/2026 at 18:01, 1 hour 49 minutes ago

Titre de mon communiqué
Published on 10/09/2026 at 18:01, 1 hour 49 minutes ago

Title of my press release
Published on 10/09/2026 at 17:45, 2 hours 5 minutes ago

Déclaration des droits de vote à fin septembre 2026

View all LES ECHOS COMFI WIRE

News